In 1938 Lord Nuffield established a Dominions Scholarship Fund, awarding scholarships to graduates from Australia, New Zealand and South Africa to work in the various Nuffield Departments. Towards the end of 1955, I was fortunate enough to be awarded one of these and to work in the Nuffield Department for two years at the time when halothane first appeared on the anaesthetic scene.
The Clinical Situation Before the Advent of Halothane
Before the advent of halothane, there was a limited range of anaesthetic agents and techniques available. Many anaesthetics given in smaller hospitals (and even in some teaching hospitals) were still open drop ether, usually, but not always, preceded by a thiopentone induction. Nitrous oxide, chloroform, trichlorethylene, ethyl chloride, ether and cyclopropane were available, each with its own limitations. The use of relaxants was still confined to major abdominal and thoracic surgery. This was a very limiting armamentarium, because, between them all, they were either nauseating, flammable, explosive, incompatible with soda lime, or were potent sources of dysrhythmias, and recovery was very slow and unpleasant. Controlled ventilation with relaxants for cranial surgery was not reported until 1957 1 .
The Background to the Development of Halothane at ICI, and the Involvement of the NDA in Clinical Trials
It had been appreciated as early as 1932 that fluorination of compounds might produce noncombustible, stable, non-toxic anaesthetic agents. The Second World War stimulated research into fluorine compounds because, among other things, hydrogen fluoride was used in the production of high-octane aviation fuel, and uranium hexafluoride was an essential intermediary in the creation of uranium-235. Both the Manhattan Project and the Mallinckrodt Co. sponsored research to produce fluorine compounds with anaesthetic potential, but without success. In 1951, Dr Charles W. Suckling 2 of the Research Department of Imperial Chemical Industries (ICI) General Chemicals Division, near Manchester, started the search for a new nonflammable anaesthetic agent, culminating in the development of halothane. He experimented with fluorinated paraffins, (existing ICI products) which were mainly used as refrigerants and aerosols. These were selected because they were stable, non-toxic, non-flammable and had a low boiling point-all desirable qualities in an anaesthetic agent. It was known that a large number of halogen atoms in a molecule would confer non-flammability and fluorine atoms would confer a low boiling-point (e.g. if all the fluorine atoms in halothane were replaced by chlorine, the boiling point would be 160°C, and therefore not sufficiently volatile). At least one hydrogen atom is required to make the compound pharmacologically active. If all the atoms were halogens, it would be inert, and more hydrogen atoms would risk flammability. Even the disposition of the atoms is relevant, as an isomer of halothane is not stable over soda lime.
With these facts in mind, Suckling developed halothane, and he and Dr James Raventos 3 subjected it to trials on mice, rats, dogs, cats and monkeys, reporting a promising profile for use as an anaesthetic agent. Halothane is a volatile, clear, colourless liquid, specific gravity 1.86, boiling point 50.2°C. The vapour has a not unpleasant odour, is non-flammable and non-explosive in air and oxygen, and will even extinguish flame.
The plies were given to Dr Michael Johnstone of Manchester, who had been an advisor to ICI, and who was, in fact, the first person to use halothane clinically, and also to Sir Robert Macintosh in Oxford. Macintosh commissioned Roger Bryce-Smith, First Assistant in the Nuffield Department, and myself, to investigate its anaesthetic properties. We were provided with an EMO vaporizer 5 , originally designed for ether, but recalibrated to accurately deliver 0.5% to 4% halothane. The recalibration was done in the NDA technical laboratory by the Senior Physicist, Dr Hans G. Epstein (the "E" in EMO) and Mr Richard Salt, Senior Technician.
It was decided that we would study the effects of halothane considered to be relevant to clinical use, viz: 1. the minimum concentration required to produce loss of consciousness, 2. the period of time required to produce loss of consciousness, 3. the concentration and duration required to allow insertion of an airway, endotracheal intubation and surgical anaesthesia, 4. the effects of various concentrations on respiration, blood pressure, electrocardiogram, neuromuscular block, and compatibility with adrenaline and other drugs, in particular, the relaxants, 5. duration of recovery, 6. post-anaesthetic effects-nausea, vomiting, headache, etc.
Design of Clinical Trials
In 1956, there was no such entity as an Ethics Committee, or even a Federal Drugs Administration. In Oxford, practising anaesthetic techniques on one's consenting colleagues or one's self was quite accepted at that time. Some staff practised blind nasal intubation under local analgesia on one another, and there were even more audacious experiments during the war. In 1943, Dr Edgar Pask (later to be Professor of Anaesthetics at Newcastle-on-Tyne), a member of the Nuffield Department and serving with the Royal Air Force, volunteered to be anaesthetized with ether to the point of respiratory arrest to assess the efficacy of several types of artificial respiration in apnoeic subjects. Later, he again volunteered to be anaesthetized and thrown into a large water tank which had a wave-making machine (at Ealing Film Studios in London), to assess the merits of different types of Mae West life-jackets for RAF pilots shot down over the sea, which would support an unconscious pilot with his face clear of the water.
In this setting, we decided to start the investigation by anaesthetizing ourselves. We set up simple experiments: for example, in order to determine the concentration at which consciousness was lost, we breathed halothane in air, gradually increasing concentrations until recall of a time marker was lost. We breathed 0.5% for five minutes without loss of consciousness, and established that the minimal concentration which reliably produced loss of consciousness was 1%. These states were identified by time markers and by application of minor painful stimuli. Blood pressure, pulse rate, ECG and respiration were monitored, the latter using a spirometer adapted from the domestic town gas meters in use at that time (Figure 4 ). We tested higher concentrations, up to 4%, to assess the potential to produce coughing, breath-holding, and laryngeal spasm, but these were notably absent. These experiments were conducted in a vacant operating room, in the afternoon after lunch. Over a period of a few weeks, we administered approximately 40 anaes- thetics to one another and a few student volunteers. The only adverse effect was that Roger Bryce-Smith vomited on one occasion.
Recovery was very rapid and we reported "a not unpleasant sensation of lassitude persisted for a few minutes" 6 .
After a few weeks we felt sufficiently confident with the drug to administer it to patients. We used halothane-air from the EMO inhaler, and also a few times by the open-drop method which was still widely in use with ether in the 1950s, especially in nonteaching hospitals. When administered to patients, a concentration of 2% provided a reasonable degree of surgical anaesthesia. There was no salivation, masseter relaxation was quick, an oral airway was tolerated quickly and intubation was usually possible within seven or eight minutes. Respiratory rate and tidal volume were severely depressed, even with 1% halothane, but surgical stimulation reversed this, suggesting that halothane had poor analgesic properties (compared with ether). We noted most of the other now well-known effects of halothane: bradycardia, rates as low as 40 beats per minute, blood pressure falls of 20% or more, but only a few ECG changes-nodal rhythm, occasional atrial ectopics and very few ventricular ectopics.
Muscle relaxation was not really adequate for laparotomy, although a few appendicectomies were done. We noted that peristalsis persisted, even under deep anaesthesia in contrast to ether.
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Anaesthesia and Intensive Care, Vol. 34, Supplement 1, June 2006 We looked for interactions with other drugs such as relaxants. The response to suxamethonium and gallamine was largely unaltered by halothane, but with d-tubocurarine, profound bradycardia and hypotension occurred, and also to a lesser extent with neostigmine. Dilute adrenaline up to 0.5 mg was infiltrated in a number of patients undergoing thyroidectomy and mastoidectomy, with only a mild tachycardia and no arrhythmia noted, although arrhythmias had been noted in animal experiments 3 . It was not until some time later when large doses of adrenaline were used in gynaecology that the incompatibility was appreciated.
We did not perform any renal or liver function tests in our series. Raventos 3 reported that the livers of animals anaesthetized with halothane for long periods, or repeatedly, had shown only minor changes, but there was no fatty degeneration as occurred with chloroform. No changes in renal function were detected.
Recovery was much more rapid than with ether or trichlorethylene, and nausea or vomiting was rare. We observed frequent shivering, at times very vigorous.
Our results were published in the British Medical Journal 6 because, unlike the British Journal of Anaesthesia, which was only published quarterly, it was published weekly and had a wider circulation.
Shortly afterwards, a meeting was held at the Royal Society of Medicine at which we reported further results and we showed a short film illustrating halothane administration 7 . At that meeting, vigorous discussion followed the presentation and Dr Michael Johnstone spoke very favourably about his experience with halothane. Professor T. Cecil Gray from Liverpool was less enthusiastic about what he called "another smelly substance".
We looked at possible problems of introduction of halothane into clinical use. Respiratory depression was a major concern because of the large number of inexperienced people then involved in anaesthesia, and its use was not initially encouraged outside teaching hospitals, even by the manufacturers, who did not want it to get a bad name.
Vaporizers were a problem because of the uncertain concentrations delivered. One of the earliest was a modified Boyle's bottle, supplied with a chart giving the approximate concentration delivered at different settings and flow rates. The Goldman Vaporizer (modelled on a carburettor), was also used, usually in the circuit, and its safety was controversial. The rather expensive Fluotec Mark 1, was the first thermocompensated and accurate vaporizer apart from the EMO, which, incidentally, incorporated a thermostatic valve used in the manufacture of Morris car engines.
Halothane dissolves in rubber, and at that time, all the anaesthetic hosing and washers in vaporizers were rubber and they rapidly rotted, causing problems with hosing slipping from connectors and jamming of vaporizer dials.
Halothane was very expensive 8 compared with ether and trichlorethylene, by about a factor of 15, and initially some hospitals would not buy it, or rationed it.
An azeotrope was prepared, (halothane/ether 2/1, boiling point 51.5°C). This caused less respiratory depression, was somewhat more economical and was popular for a few years.
We did not use halothane in obstetrics and some time elapsed before it was realised that halothane relaxed uterine muscle, with resulting haemorrhage. Halothane was easy to use, minimally nauseating and irritating but always treated with respect because of its potency and side-effects. It enabled significant advances in surgery, especially thoracic surgery and neurosurgery, because being non-flammable, it permitted safe use of the diathermy in areas where previously it could not be used, making operations quicker and safer, haemostasis more reliable, and recovery quicker. halothane, "for the first time, the anaesthetist had an agent that was non-combustible, relatively nontoxic, and which allowed rapid and clear-headed recovery. It cannot be over-emphasised how much of an advance was the introduction of halothane into clinical anaesthesia."
